IDEC-Y2B8 radioimmunotherapy: Phase I/II data; Phase III ongoing

IDPH said that Phase I/II results of the combined therapy in 51 patients showed overall response rates in low grade or

Read the full 212 word article

How to gain access

Continue reading with a
two-week free trial.